Dr Reddy's relaunches generic acid reflux drug in USThe company has "relaunched its Esomeprazole Magnesium delayed-release capsules in the US market. The relaunch is due to a change in the ca...
Dr Reddy's countersues AstraZeneca over purple pillDr Reddy's Laboratories, has filed a complaint in a US court alleging that AstraZeneca "knew" about its plans to use the same colour in the...
The colour purple that has left drug makers like Dr Reddy's Laboratories paleThe reference here has nothing to do with the Pulitzer-winning book of Alice Walker, but the actual colour that has pushed big pharma to pu...
US court imposes temporary sales ban on Dr Reddy’s generic antacidThe order has come on a suit filed by AstraZeneca, which objected to the Indian company using purple colour for the generic version.
Lupin gets USFDA nod for generic ulcer drugDrug firm Lupin has received approval from US health regulator USFDA to market generic Omeprazole delayed-release capsules, used to treat u...
Aurobindo Pharma gets USFDA nod to market ulcer drugThe company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, it a...
'One-fifth of stomach ailment patients can be given simpler cure'Aimed at bringing international standards to the care of patients suffering from functional bowel disease, the institute is hosting a three...
Glenmark Generics gets US FDA nod for ulcer treatment drugGlenmark's current portfolio consists of 94 products authorised for distribution in the US market and 72 ANDAs are pending approval with th...
- ICICI Securities retains buy reating on Dr Reddy's Laboratories
ICICI Securities (I-Sec) has retained its 'buy' rating on pharma major Dr Reddy's Laboratories, with a price target of Rs 495.
- Analyst's Pick: Dr Reddy's Laboratories
Citigroup recommends 'Hold' rating on Dr Reddy’s Laboratories with a target price of Rs 547.
- Dr Reddy’s surges 5% on winning Omeprazole case
Shares of Dr Reddy’s Laboratories were on the rise after the US district court ruled in its favour in a case related to Omeprazole for whic...
- Post USFDA ban, Ranbaxy readies plan B for drugs
Ranbaxy may shift production of the $1.5-billion drug Valacyclovir to its other FDA- approved facilities. The Top 10 food myths revealed | ...
- Ranbaxy launches generic anti-ulcer drug
Ranbaxy has launched generic versions of Astrazeneca’s anti-ulcer drug Prilosec 40 mg in the US.
- Ranbaxy shares zoom 3% on ulcer drug launch
Shares of Ranbaxy Laboratories gained over 3 per cent after the pharmaceutical major announced the launch of a generic version of an ulcer ...
- AstraZeneca denied patent for anti-ulcer drug
The Indian patent office has turned down the company’s patent application for a new formulation of anti-ulcer drug Omeprazole.
- Mylan buys Merck’s generics unit
Mylan Laboratories agreed to buy Merck KGaA’s generic-drug unit for 4.9 billion euros ($6.7 billion) in cash to become the world’s third-la...
- Pharma action hots up: UCB acquires Schwarz for $5.6bn
UCB, the Belgian maker of the allergy drug Zyrtec, agreed to buy Schwarz Pharma for E4.4bn ($5.6bn) in cash and stock to gain new medicines...